Resveratrol Reduces Morphologic Changes in the Myenteric Plexus and Oxidative Stress in the Ileum in Rats with Ischemia/Reperfusion Injury

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3252-3263

  da Silva de Souza, Aline Cristine ^a   Borges, Stephanie Carvalho ^a   Beraldi, Evandro José ^a   de Sá Nakanishi, Anacharis Babeto ^a   Comar, Jurandir Fernando ^a   Bracht, Adelar ^a   Natali, Maria Raquel Marçal ^a   Buttow, Nilza Cristina ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Ileum; Ischemia reperfusion injury; Neuroprotection; Oxidative stress; Resveratrol

Indexed keywords

ANTIOXIDANT; CATALASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LIPID PEROXIDE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; RESVERATROL; VASOACTIVE INTESTINAL POLYPEPTIDE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL BODY; CELL DENSITY; CELL POPULATION; CELL SHAPE; CELL STRUCTURE; CELL SWELLING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; GLIA CELL; ILEUM; MALE; MESENTERIC ISCHEMIA; MORPHOMETRICS; MYENTERIC PLEXUS; NEUROPROTECTION; NITRERGIC NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN LOCALIZATION; RAT; REPERFUSION INJURY; TISSUE LEVEL; TISSUE STRUCTURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ILEAL DISEASES; INNERVATION; LIPID PEROXIDATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROTEIN CARBONYLATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; ILEAL DISEASES; ILEUM; LIPID PEROXIDATION; MALE; MYENTERIC PLEXUS; NEUROPROTECTIVE AGENTS; NITRERGIC NEURONS; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS, WISTAR; REPERFUSION INJURY; STILBENES;

EID: 84945446009     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3742-5     Document Type: Article

References (54)

1. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: a review. Acta Cir Bras. 2005;20:336–343.
2. Koike K, Moore FA, Moore EE, Read RA, Carl VS, Banerjee A. Gut ischemia mediates lung injury by a xanthine oxidase-dependent neutrophil mechanism. J Surg Res. 1993;54:469–473.
3. Chang RW, Chang JB, Longo WE. Update in management of mesenteric ischemia. World J Gastroenterol. 2006;12:3243–3247.
4. McCord JM. The superoxide free radical: its biochemistry and pathophysiology. Surgery. 1983;94:412–414.
5. Takizawa Y, Kitazato T, Kishimoto H, Tomita M, Hayashi M. Effects of antioxidants on drug absorption in in vivo intestinal ischemia/reperfusion. Eur J Drug Metab Pharmacokinet. 2011;35:89–95.
6. Guzmán-De La Garza FJ, Cámara-Lemarroy CR, Ballesteros-Elizondo RG, Alarcón-Galván G, Cordero-Pérez P, Fernández-Garza NE. Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats. Surg Today. 2010;40:1055–1062.
7. Tóth S, Jonecová Z, Varga J, et al. Mesenteric ischemia–reperfusion injury: specific impact on different cell populations within the jejunal wall in rats. Acta Histochem. 2012;114:276–284.
8. Lindeström LM, Ekblad E. Structural and neuronal changes in rat ileum after ischemia with reperfusion. Dig Dis Sci. 2004;49:1212–1222.
9. Thacker M, Rivera LR, Cho HJ, Furness JB. The relationship between glial distortion and neuronal changes following intestinal ischemia and reperfusion. Neurogastroenterol Motil. 2011;23:e500–e509.
10. Rivera LR, Thacker M, Castelucci P, Bron R, Furness JB. The reactions of specific neuron types to intestinal ischemia in the guinea pig enteric nervous system. Acta Neuropathol. 2009;118:261–270.
11. Wang F, Li Q, Wang C, Tang C, Li J. Dynamic alteration of the colonic microbiota in intestinal ischemia–reperfusion injury. PLoS One. 2012;7:e42027.
12. Pontell L, Sharma P, Rivera LR, et al. Damaging effects of ischemia/reperfusion on intestinal muscle. Cell Tissue Res. 2011;343:411–419.
13. Kuenzler KA, Pearson PY, Schwartz MZ. IL-11 pretreatment reduces cell death after intestinal ischemia–reperfusion. J Surg Res. 2002;108:268–272.
14. Silva MA, de Meirelles LR, Bustorff-Silva JM. Changes in intestinal motility and in the myenteric plexus in a rat model of intestinal ischemia–reperfusion. J Pediatr Surg. 2007;42:1062–1065.
15. Miller NJ, Rice-Evans CA. Antioxidant activity of resveratrol in red wine. Clin Chem. 1995;41:1789.
16. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998;273:21875–21882.
17. Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett. 2000;281:123–126.
18. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002;71:655–665.
19. Saleh MC, Connell BJ, Rajagopal D, et al. Co-administration of resveratrol and lipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusion. PLoS One. 2014;9:e87865.
20. Zheng Y, Liu Y, Ge J, et al. Resveratrol protects human lens epithelial cells against h2o2-induced oxidative stress by increasing catalase, sod-1, and ho-1 expression. Mol Vis. 2010;16:1467–1474.
21. Karabulut AB, Kirimlioglu V, Kirimlioglu H, Yilmaz S, Isik B, Isikgil O. Protective effects of resveratrol on spleen and ileum in rats subjected to ischemia-reperfusion. Transplant Proc. 2006;38:375–377.
22. Gedik E, Girgin S, Ozturk H, Obay BD, Buyukbayram H. Resveratrol attenuates oxidative stress and histological alterations induced by liver ischemia/reperfusion in rats. World J Gastroenterol. 2008;14:7101–7106.
23. Della-Morte D, Dave KR, DeFazio RA, et al. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159:993–1002.
24. Huang W, Li G, Qiu J, Gonzalez P, Challa P. Protective effects of resveratrol in experimental retinal detachment. PLoS One. 2013;8:e75735.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–275.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
27. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478.
28. Pardo-Andreu GL, Cavalheiro RA, Dorta DJ, et al. Fe(III) shifts the mitochondria permeability transition-eliciting capacity of mangiferin to protection of organelle. J Pharmacol Exp Ther. 2007;320:646–653.
29. Aebi H, Wyss SR, Scherz B, Skvaril F. Heterogeneity of erythrocyte catalase ii. Isolation and characterization of normal and variant erythrocyte catalase and their subunits. Eur J Biochem. 1974;48:137–145.
30. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–169.
31. Tappel AL. Glutathione peroxidase and hydroperoxides. Methods Enzymol. 1978;52:506–513.
32. Bergmeyer HU: Methods of Enzymatic Analysis. New York, Weinheim: Academic Press, Verlag Chemie; 1974:1205–1214, 2nd English edition.
33. Ozkan OV, Yuzbasioglu MF, Ciralik H, et al. Resveratrol, a natural antioxidant, attenuates intestinal ischemia/reperfusion injury in rats. Tohoku J Exp Med. 2009;218:251–258.
34. Comar JF, Babeto de Sa-Nakanishi A, de Oliveira AL, et al. Oxidative state of the liver of rats with adjuvant-induced arthritis. Free Radic Biol Med. 2013;58:144–153.
35. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. London: Oxford University Press; 2007.
36. Harward TR, Coe D, Souba WW, Klingman N, Seeger JM. Glutamine preserves gut glutathione levels during intestinal ischemia/reperfusion. J Surg Res. 1994;56:351–355.
37. Shan XQ, Aw TY, Jones DP. Glutathione-dependent protection against oxidative injury. Pharmacol Ther. 1990;47:61–71.
38. Gibson DD, Brackett DJ, Squires RA, et al. Evidence that the large loss of glutathione observed in ischemia/reperfusion of the small intestine is not due to oxidation to glutathione disulfide. Free Radic Biol Med. 1993;14:427–433.
39. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294:L478–L488.
40. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans. 2007;35:1156–1160.
41. Yen GC, Duh PD, Lin CW. Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res. 2003;37:509–514.
42. Brito PM, Mariano A, Almeida LM, Dinis TC. Resveratrol affords protection against peroxynitrite-mediated endothelial cell death: a role for intracellular glutathione. Chem Biol Interact. 2006;164:157–166.
43. Quincozes-Santos A, Gottfried C. Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann NY Acad Sci. 2011;1215:72–78.
44. Rivera LR, Thacker M, Pontell L, Cho HJ, Furness JB. Deleterious effects of intestinal ischemia/reperfusion injury in the mouse enteric nervous system are associated with protein nitrosylation. Cell Tissue Res. 2011;344:111–123.
45. Kristián T, Siesjö BK. Calcium in ischemic cell death. Stroke. 1998;29:705–718.
46. Tong Q, Kirchgessner AL. Localization and function of metabotropic glutamate receptor 8 in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2003;285:G992–G1003.
47. Liu B, Liao M, Mielke JG, et al. Ischemic insults direct glutamate receptor subunit 2-lacking ampa receptors to synaptic sites. J Neurosci. 2006;26:5309–5319.
48. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Calcium in cell injury and death. Annu Rev Pathol. 2006;1:405–434.
49. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56:249–290.
50. Sandgren K, Lin Z, Fex Svenningsen A, Ekblad E. Vasoactive intestinal peptide and nitric oxide promote survival of adult rat myenteric neurons in culture. J Neurosci Res. 2003;72:595–602.
51. Ekblad E, Bauer AJ. Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity. Neurogastroenterol Motil. 2004;16:123–128.
52. Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in hk2 human renal cells. Peptides. 2012;38:275–281.
53. Kalfin R, Maulik N, Engelman RM, et al. Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. J Pharmacol Exp Ther. 1994;268:952–958.
54. Alves EP, Alves AM, Pereira RV, de Miranda Neto MH, Zanoni JN. Immunohistochemical study of vasoactive intestinal peptide (vip) enteric neurons in diabetic rats supplemented with l-glutamine. Nutr Neurosci. 2010;13:43–51.